{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T10:36:46Z","timestamp":1769164606695,"version":"3.49.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TRR237-369799452"],"award-info":[{"award-number":["TRR237-369799452"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KO2155\/6-1"],"award-info":[{"award-number":["KO2155\/6-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KO2155\/7-1"],"award-info":[{"award-number":["KO2155\/7-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1038\/s41375-023-01837-9","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T08:06:32Z","timestamp":1677225992000},"page":"924-928","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-\u03b1: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN)"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2157-476X","authenticated-orcid":false,"given":"Frank","family":"Stegelmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9489-7282","authenticated-orcid":false,"given":"Lino L.","family":"Teichmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian H.","family":"Heidel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl C.","family":"Crodel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2147-489X","authenticated-orcid":false,"given":"Thomas","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Kreil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Otten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Schauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth-Miriam","family":"K\u00f6rber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Kricheldorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Isfort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2116-5536","authenticated-orcid":false,"given":"Hartmut","family":"D\u00f6hner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9677-3723","authenticated-orcid":false,"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Griesshammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2261-9862","authenticated-orcid":false,"given":"Konstanze","family":"D\u00f6hner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1011-8171","authenticated-orcid":false,"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,24]]},"reference":[{"key":"1837_CR1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/ejh.13373","volume":"104","author":"E Ahlstrand","year":"2020","unstructured":"Ahlstrand E, Samuelsson J, Lindgren M, Pettersson H, Liljeholm M, Ravn-Landtblom A, et al. Highly reduced survival in essential thrombocythemia and polycythemia vera patients with vascular complications during follow-up. Eur J Haematol. 2020;104:271\u20138.","journal-title":"Eur J Haematol"},{"key":"1837_CR2","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124:2507\u201313.","journal-title":"Blood"},{"key":"1837_CR3","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41375-020-0945-3","volume":"35","author":"F Stegelmann","year":"2021","unstructured":"Stegelmann F, Wille K, Busen H, Fuchs C, Schauer S, Sadjadian P, et al. Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN. Leukemia. 2021;35:628\u201331.","journal-title":"Leukemia"},{"key":"1837_CR4","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1038\/s41375-021-01183-8","volume":"35","author":"G Abu-Zeinah","year":"2021","unstructured":"Abu-Zeinah G, Krichevsky S, Cruz T, Hoberman G, Jaber D, Savage N, et al. Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. Leukemia. 2021;35:2592\u2013601.","journal-title":"Leukemia"},{"key":"1837_CR5","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41375-021-01447-3","volume":"36","author":"G Abu-Zeinah","year":"2022","unstructured":"Abu-Zeinah G, Silver RT, Abu-Zeinah K, Scandura JM. Normal life expectancy for polycythemia vera (PV) patients is possible. Leukemia. 2022;36:569\u201372.","journal-title":"Leukemia"},{"key":"1837_CR6","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","volume":"27","author":"A Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009;27:5418\u201324.","journal-title":"J Clin Oncol"},{"key":"1837_CR7","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.1016\/S2352-3026(17)30030-3","volume":"4","author":"L Masarova","year":"2017","unstructured":"Masarova L, Patel KP, Newberry KJ, Cortes J, Borthakur G, Konopleva M, et al. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. Lancet Haematol. 2017;4:e165\u2013e175.","journal-title":"Lancet Haematol"},{"key":"1837_CR8","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1182\/blood-2015-07-659060","volume":"126","author":"E Verger","year":"2015","unstructured":"Verger E, Cassinat B, Chauveau A, Dosquet C, Giraudier S, Schlageter MH, et al. Clinical and molecular response to interferon alpha therapy in essential thrombocythemia patients with CALR mutations. Blood. 2015;126:2585\u201391.","journal-title":"Blood"},{"key":"1837_CR9","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41375-020-01020-4","volume":"35","author":"JP Bewersdorf","year":"2021","unstructured":"Bewersdorf JP, Giri S, Wang R, Podoltsev N, Williams RT, Tallman MS, et al. Interferon alpha therapy in essential thrombocythemia and polycythemia vera-a systematic review and meta-analysis. Leukemia. 2021;35:1643\u201360.","journal-title":"Leukemia"},{"key":"1837_CR10","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","volume":"120","author":"T Barbui","year":"2012","unstructured":"Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120:5128\u201333.","journal-title":"Blood"},{"key":"1837_CR11","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29:761\u201370.","journal-title":"J Clin Oncol"},{"key":"1837_CR12","doi-asserted-by":"publisher","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","volume":"113","author":"G Barosi","year":"2009","unstructured":"Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009;113:4829\u201333.","journal-title":"Blood"},{"key":"1837_CR13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/978-1-4939-7778-9_15","volume":"1768","author":"E Kinz","year":"2018","unstructured":"Kinz E, Muendlein A. Quantitation of JAK2 V617F allele burden by using the QuantStudio\u2122 3D Digital PCR System. Methods Mol Biol. 2018;1768:257\u201373.","journal-title":"Methods Mol Biol"},{"key":"1837_CR14","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3109\/10428194.2015.1049171","volume":"57","author":"C Utke Rank","year":"2016","unstructured":"Utke Rank C, Weis Bjerrum O, Larsen TS, Kj\u00e6r L, de Stricker K, Hasselbalch Riley C, et al. Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera. Leuk Lymphoma. 2016;57:348\u201354.","journal-title":"Leuk Lymphoma"},{"key":"1837_CR15","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41375-022-01528-x","volume":"36","author":"JJ Kiladjian","year":"2022","unstructured":"Kiladjian JJ, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b. Leukemia. 2022;36:1408\u201311.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01837-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01837-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01837-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T11:09:20Z","timestamp":1680779360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01837-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,24]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1837"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-01837-9","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,24]]},"assertion":[{"value":"17 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FS reports honoraria from and consultancy for Abbvie, AOP Pharma, BMS\/Celgene, Incyte, Novartis, and Pfizer. LLT reports honoraria from AOP Pharma, BMS, Boehringer Ingelheim, and Sobi and consultancy for Astellas, BMS, Pfizer, and Sobi. FHH received research funding from BMS\/Celgene, CTI, and Novartis and served as a consultant for AOP, BMS\/Celgene, CTI, Incyte, Novartis, Pfizer, Abbvie, Janssen, Kartos, and MatterBio. CCC reports honoraria from and consultancy for Novartis, BMS\/Celgene, and AstraZeneca. TE received travel\/accommodation support from Janssen. AR received research funding from Blueprint Medicines, Novartis, BMS\/Celgene, Incyte, AbbVie, AOP, and GSK, honoraria from Blueprint Medicines, Novartis, BMS\/Celgene, Incyte, AOP, and GSK and has served on advisory boards for Blueprint Medicines, Novartis, BMS\/Celgene, Incyte, AbbVie, and AOP. RMK received honoraria from Stemline and Sobi. SI reports advisory board honoraria from Pfizer, Incyte, and Novartis, honoraria from Novartis, BMS, Pfizer, and Incyte and other financial support (e.g., travel support) from Alexion, Novartis, Pfizer, Mundipharma, Roche, and Hexal. HD reports advisory role for Abbvie, Agios, Amgen, Astellas, AstraZeneca, Berlin-Chemie, BMS, Celgene, GEMoaB, Gilead, Janssen, Jazz Pharmaceuticals, Novartis, and Syndax and research funding from Abbvie, Agios, Amgen, Astellas, BMS, Jazz Pharmaceuticals, Kronos-Bio, and Novartis. THB served as a consultant for Janssen, Merck, Novartis, and Pfizer, received research funding from Novartis, and Pfizer and honorarium from Pfizer. MG reports speaker bureau and consultancy for AOP Orphan, Celgene, CTI, Novartis, and Shire. KD reports speaker bureau and consultancy for BMS, Celgene, CTI, Novartis, and Roche. S Koschmieder received research grant\/funding from Geron, Janssen, AOP Pharma, and Novartis, consulting fees from Pfizer, Incyte, Ariad, Novartis, AOP Pharma, BMS, Celgene, Geron, Janssen, CTI, Roche, Bayer, and PharmaEssentia; received payment or honoraria from Novartis, BMS\/Celgene, Pfizer; received travel\/accommodation support from Alexion, Novartis, BMS, Incyte, AOP Pharma, CTI, Pfizer, Celgene, Janssen, Geron, Roche, AbbVie, Imago Biosciences, Sierra Oncology, and Karthos; had a patent issued for a BET inhibitor at RWTH Aachen University; participated on advisory boards for Pfizer, Incyte, Ariad, Novartis, AOP Pharma, BMS, Celgene, Geron, Janssen, CTI, Roche, Bayer, AbbVie, Sierra Oncology, Karthos, Imago Bioscience, and PharmaEssentia. S Kreil, SO, SS, and KK declare that they have no competing interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}